NCT07077083View on ClinicalTrials.gov

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions
Clear Cell Renal Cell Carcinoma (ccRCC)ccRCC
Interventions
DRUG

89Zr-Girentuximab

89Zr-Girentuximab PET

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Telix Pharmaceuticals, Ltd

UNKNOWN

lead

Massachusetts General Hospital

OTHER